Lyra Therapeutics (LYRA) Misses Q1 EPS by 9c

Lyra Therapeutics (NASDAQ: LYRA) reported Q1 EPS of ($0.35), $0.09 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $530 thousand versus the consensus estimate of $345.75 thousand.

For earnings history and earnings-related data on Lyra Therapeutics (LYRA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49